C3: Complement C3
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. {ECO:0000269|PubMed:12878586, ECO:0000269|PubMed:18204047, ECO:0000269|PubMed:28264884, ECO:0000269|PubMed:31507604, ECO:0000269|PubMed:39814882, ECO:0000269|PubMed:39914456, ECO:0000269|PubMed:624565, ECO:0000269|PubMed:6554279}.
- Drugs that act on it: 3
- Approved: 1
- In phases 1 to 3: 2
- Sponsors: 3
Who Is On It, and How Far Along
Every drug ChEMBL records acting on C3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide
- Other
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Complement C3 inhibitor.| Pegcetacoplan | Approved | Apellis Pharmaceuticals | Protein or peptide | Inhibitor | — | 14 | Boxed warning |
| AL-78898A | Phase 2 | Alcon | Other | Inhibitor | — | 0 | — |
| AMY-101 | Phase 2 | Amyndas Pharmaceuticals S.A. | Protein or peptide | Inhibitor | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Atypical hemolytic-uremic syndrome with C3 anomaly
- 0.80
- Complement component 3 deficiency
- 0.77
- Age-related macular degeneration
- 0.74
- Complement 3 glomerulopathy
- 0.60
- Atypical hemolytic-uremic syndrome
- 0.59
- Age related macular degeneration 9
- 0.56
- Retinal disorder
- 0.56
- Atrophic macular degeneration
- 0.55
- Degeneration of macula and posterior pole
- 0.54
- COVID-19
- 0.51
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4917, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P01024, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets